This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sponsored by World Molecular Imaging Society and the Beth Israel Deaconess Medical Center of Harvard Medical SchoolBOSTON,
Oct. 21, 2013 /PRNewswire-USNewswire/ -- Molecular imaging holds the promise for improved patient management in medicine and surgery. To realize this goal, a thorough understanding of the instrumentation and diagnostic agents that comprise the field is necessary. Emerging methodologies in molecular imaging that could become part of clinical practice within the next decade
will be highlighted at the
Advanced Molecular Imaging and Its Clinical Translation course, here at the Fairmont Copley Plaza,
October 27-30, 2013.
Sponsored by the World Molecular Imaging Society (WMIS) and the Department of Medicine at Beth Israel Deaconess Medical Center (BIDMC) /
Harvard Medical School, the Advanced Molecular Imaging and its Clinical Translation Course
brings together some of the most
influential thought leaders and provides a comprehensive educational experience in the
physics, chemistry, engineering, and physiology that are
the foundation of molecular imaging. Key
leaders from industry will bring their perspective on how
intellectual property, regulatory approval, and reimbursement
impact patient care. Faculty from around the world specializing
in basic science, clinical translation, and clinical applications
have been carefully chosen to bring course attendees to the state-of-the-art in the field.
"Imaging and biomarker application is at the core of the pursuit of translational medicine. Clinical translation is a focus for WMIS in 2014 and partnering with
Harvard Medical School allows us to extend our educational offerings and create a greater awareness of molecular imaging and its use in defining precision medicine," said
Anna M. Wu, Ph.D., President of WMIS, Professor and Vice Chair of Molecular and Medical Pharmacology and Associate Director of Crump Institute for Molecular Imaging at the David Geffen School of Medicine,
Most aspects of molecular imaging will be covered, including optical imaging, SPECT, PET, CT, MRI, ultrasound, combinations thereof, contrast agent chemistry, radiotracer development, preclinical imaging, regulatory, statistical, reimbursement, and logistical issues surrounding clinical translation, and state-of-the-art clinical imaging in cancer, heart disease, neurology, and other human conditions.